Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)

被引：3

作者：

Antonuzzo, L. ^{[1
,2
]}

Takahashi, H. ^{[3
]}

Park, J. O. ^{[4
]}

Sookprasert, A. ^{[5
]}

Gillmore, R. ^{[6
]}

Yang, S-S. ^{[7
]}

Cundom, J. E. ^{[8
]}

Petrova, M. ^{[9
]}

Vaccaro, G. M. ^{[10
]}

Holmblad, M. ^{[11
]}

Xiong, J. ^{[12
]}

Heider, K. ^{[13
]}

Rokutanda, N. ^{[11
]}

Oh, D-Y. ^{[14
,15
]}

机构：

[1] Univ Florence, Dept Expt & Clin Med, Florence, Italy

[2] Univ Florence, Careggi Univ Hosp, Clin Oncol Unit, Florence, Italy

[3] Osaka Int Canc Inst, Dept Gastroenterol Surg, Osaka, Japan

[4] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea

[5] Khon Kaen Univ, Dept Med, Med Oncol Unit, Fac Med, Khon Kaen, Thailand

[6] Royal Free Hosp, Dept Med Oncol, London, England

[7] Taichung Vet Gen Hosp, Div Gastroenterol, Dept Internal Med, Taichung, Taiwan

[8] Inst Invest Metab, Dept Med Oncol, Buenos Aires, Argentina

[9] MHAT Nadezhda, Dept Med Oncol, Sofia, Bulgaria

[10] Providence Canc Inst, Med Oncol & Hematol Oncol, Portland, OR USA

[11] AstraZeneca, Clin Res, Gaithersburg, MD USA

[12] AstraZeneca, Clin Res, Waltham, MA USA

[13] AstraZeneca, Clin Res, Cambridge, England

[14] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea

[15] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Div Med Oncol,Dept Internal Med, Seoul, South Korea

来源：

关键词：

D O I：

10.1016/j.annonc.2022.07.085

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

57P

引用

页码：S566 / S567

页数：2